BioNTech's 21% Pop Poses an Awkward Question: Whose Victory Was It?

BioNTech shares jump 21% on rival's melanoma data, but analysts split on whether the rally is sustainable amid shrinking Covid revenue and upcoming oncology catalysts.

When a stock jumps a fifth of its value in a single session, the market is usually rewarding the company itself. For BioNTech, Wednesday's surge was more complicated: the trigger came from rivals Moderna and Merck, whose Phase 3 melanoma data for a personalized mRNA cancer therapy landed with force. BioNTech's shares closed at €96.75, riding a sector-wide wave of enthusiasm and the hope that its own oncology pipeline might benefit from similar momentum.

The complication is timing. The rally extends a run that began roughly three weeks ago, when the company announced Guido Oelkers would take over as CEO — a move that has since added 23.2% to the share price. Before that, the stock had been digesting a cut to full-year guidance and a bruising second quarter that produced a net loss of €820.8 million. Since that downgrade landed about two weeks ago, shares have climbed 22.5%. Wednesday's move, in other words, is the latest in a sequence of supportive headlines layered on top of a structurally shrinking revenue base.

That tension frames the central question for investors: does the Moderna/Merck result genuinely validate BioNTech's own mRNA oncology programs, or is the jump a sector reflex with little company-specific substance behind it? The answer will determine whether the 21% gain holds or erodes in the weeks ahead.

Canaccord Genuity sees reasons for optimism, pointing to three oncology data readouts expected before year-end that could serve as the next catalysts. The firm lifted its price target to $142 on Wednesday and reiterated a buy rating, citing both the upcoming data and the leadership transition under Oelkers. Leerink Partners strikes a more cautious tone, arguing that the Moderna/Merck signal has limited transferability — BioNTech's own iNEST program, developed with Roche, previously delivered disappointing results.

The bull case rests on a simple premise: if interim data from BioNTech's oncology studies confirm the promise, the rally could mark the start of a more durable re-rating. The company's €19.85 billion market capitalization would still leave room to run, particularly with shares trading 8.6% below their 52-week high of €105.80. Supporting the narrative is the European Commission's August approval of an updated Covid-19 vaccine developed with Pfizer, adapted for the XFG variant — evidence that the core business, while diminished, has not ground to a halt.

The pipeline itself offers a broader foundation. Management points to 14 ongoing registration-enabling studies, six new trial starts this year, and three additional late-stage readouts expected in 2026. A recent Phase 2 evaluation of Pumitamig in non-small cell lung cancer showed a confirmed objective response rate of 62.5% across PD-L1 expression levels — a solid clinical data point that reinforces the diversified oncology story.

The bear case is equally clear-eyed. Annualized volatility sits at roughly 64%, and the relative strength index has pushed toward 80 — territory that historically precedes profit-taking. The guidance cut to €1.6–1.9 billion in annual revenue remains in place, a reflection of fading demand for pandemic-era products. Second-quarter revenue came in at just €106 million, with losses widening year over year on the back of declining US Covid-19 vaccine uptake and the absence of a one-time Pfizer payment that had boosted the prior-year period.

Should Leerink's skepticism prove warranted — if BioNTech's own data disappoints — the pullback could be sharp, given that much of the recent move rests on news from other companies rather than BioNTech's own results. A correction toward the moving averages around €80–84 is plausible in that scenario.

What tempers the downside risk is the balance sheet. BioNTech holds €16.6 billion in cash and securities, supplemented by an expected €613 million from its collaboration with Bristol Myers Squibb in the third quarter. That war chest buys time to execute the oncology strategy without needing to raise fresh capital. A share buyback program of up to $1 billion, of which $152 million has already been executed, signals management's confidence in the current valuation.

The stock now sits 8.5% below its 52-week high but 42% above its yearly low — a measure of how violently it swings in both directions. The next sector-wide catalyst arrives on November 14, 2026, when the FDA is scheduled to rule on Summit Therapeutics' Ivonescimab, a competing oncology product whose outcome could influence sentiment across mRNA-based approaches, including BioNTech's.

For now, the market is choosing to look past the shrinking Covid franchise and focus on what the pipeline might become. Whether that optimism survives contact with BioNTech's own data — and the competitive dynamics of a field where it is far from alone — is the test the coming months will deliver.